| Crohn Disease

Entyvio vs Humira

Side-by-side clinical, coverage, and cost comparison for crohn disease.

Deep comparison between: Entyvio vs Humira with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHumira has a higher rate of injection site reactions vs Entyvio based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Humira but not Entyvio, including UnitedHealthcare

Category

Entyvio

Humira

At A Glance

RouteIV infusion or SC injection

FrequencyEvery 2 weeks (SC) or every 8 weeks (IV)

Classalpha4beta7 integrin antagonist

RouteSC injection

FrequencyEvery other week

ClassTNF-alpha antagonist

Indications

Ulcerative Colitis
Crohn Disease

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Chronic small plaque psoriasis
Hidradenitis Suppurativa
Uveitis

Dosing

Ulcerative Colitis, Crohn Disease Week 0 and Week 2: 300 mg IV infusion over approximately 30 minutes; Week 6 onwards: 300 mg IV infusion every 8 weeks or 108 mg SC injection every 2 weeks; discontinue if no evidence of therapeutic benefit by Week 14.

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may increase to 40 mg every week or 80 mg every other week.

Juvenile arthritis, Uveitis (pediatric) Weight-based SC dosing every other week: 10 mg (10 kg to <15 kg), 20 mg (15 kg to <30 kg), or 40 mg (>=30 kg) for patients 2 years of age and older.

Crohn Disease 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.

Ulcerative Colitis 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by 8 weeks (Day 57).

Chronic small plaque psoriasis, Uveitis 80 mg SC initial dose, then 40 mg every other week starting 1 week after the initial dose.

Hidradenitis Suppurativa 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Contraindications

Known serious or severe hypersensitivity reaction to vedolizumab or any excipient (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased heart rate)

—

Drug Interactions

379View drug interactions

1223View drug interactions

Adverse Reactions

Most common (>=3%) nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities

Serious infusion-related reactions including anaphylaxis, infections (anal abscess, sepsis, tuberculosis, Listeria meningitis, giardiasis, cytomegaloviral colitis), liver injury (elevated transaminases, hepatitis), malignancies

Postmarketing anaphylaxis, acute pancreatitis, interstitial lung disease, pneumonitis

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, sinusitis, urinary tract infection, nausea, hyperlipidemia, abdominal pain, flu syndrome, hypercholesterolemia, back pain.

Serious Serious infections (pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, severe hepatic reactions including acute liver failure, new-onset lupus-like syndrome.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.

Pharmacology

Vedolizumab is a humanized IgG1 monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibiting the migration of memory T-lymphocytes into inflamed gastrointestinal tissue; the mechanism is gut-selective and does not affect the alpha4beta1 or alphaEbeta7 integrins or VCAM-1 interactions.

Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha, blocking its interaction with the p55 and p75 cell surface TNF receptors and inhibiting TNF-mediated inflammatory and immune responses, including modulation of adhesion molecules responsible for leukocyte migration.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Entyvio